102 related articles for article (PubMed ID: 38321542)
1. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
Shah SS; Wang Y; Tull J; Zhang S
Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
[TBL] [Abstract][Full Text] [Related]
2. HER2 targeted therapy in colorectal Cancer: Current landscape and future directions.
Chen N; He L; Zou Q; Deng H
Biochem Pharmacol; 2024 May; 223():116101. PubMed ID: 38442793
[TBL] [Abstract][Full Text] [Related]
3. High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer.
Tanei T; Seno S; Sota Y; Hatano T; Kitahara Y; Abe K; Masunaga N; Tsukabe M; Yoshinami T; Miyake T; Shimoda M; Matsuda H; Shimazu K
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473420
[TBL] [Abstract][Full Text] [Related]
4. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
Marín-Aguilera M; Jares P; Sanfeliu E; Villacampa G; Hernández-Lllán E; Martínez-Puchol AI; Shankar S; González-Farré B; Waks AG; Brasó-Maristany F; Pardo F; Manning DK; Abery JA; Curaba J; Moon L; Gordon O; Galván P; Wachirakantapong P; Castillo O; Nee CM; Blasco P; Senevirathne TH; Sirenko V; Martínez-Sáez O; Aguirre A; Krop IE; Li Z; Spellman P; Metzger Filho O; Polyak K; Michaels P; Puig-Butillé JA; Vivancos A; Matito J; Buckingham W; Perou CM; Villagrasa-González P; Prat A; Parker JS; Paré L
ESMO Open; 2024 Mar; 9(3):102903. PubMed ID: 38452436
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological and morphological modulation of neuronal-glial network by breast cancer and nontumorigenic mammary cell conditioned medium.
Di Lisa D; Cortese K; Chiappalone M; Arnaldi P; Martinoia S; Castagnola P; Pastorino L
Front Bioeng Biotechnol; 2024; 12():1368851. PubMed ID: 38638322
[TBL] [Abstract][Full Text] [Related]
6. Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.
Kang CC; Ward TM; Bockhorn J; Schiffman C; Huang H; Pegram MD; Herr AE
NPJ Precis Oncol; 2018; 2():10. PubMed ID: 29872719
[TBL] [Abstract][Full Text] [Related]
7. HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
Xu QQ; Pan B; Wang CJ; Zhou YD; Mao F; Lin Y; Guan JH; Shen SJ; Zhang XH; Xu YL; Zhong Y; Wang XJ; Zhang YN; Sun Q
Oncotarget; 2016 Sep; 7(39):63571-63582. PubMed ID: 27566580
[TBL] [Abstract][Full Text] [Related]
8. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.
Rönnlund C; Sifakis EG; Schagerholm C; Yang Q; Karlsson E; Chen X; Foukakis T; Weidler J; Bates M; Fredriksson I; Robertson S; Hartman J
Breast Cancer Res; 2024 Feb; 26(1):24. PubMed ID: 38321542
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
12. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract][Full Text] [Related]
13. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
Seo J; Koh J; Lee DW; Kim J; Ryu HS; Lee KH; Kim TY; Im SA
Breast Cancer Res; 2023 Dec; 25(1):154. PubMed ID: 38098054
[TBL] [Abstract][Full Text] [Related]
14. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
Mosele F; Deluche E; Lusque A; Le Bescond L; Filleron T; Pradat Y; Ducoulombier A; Pistilli B; Bachelot T; Viret F; Levy C; Signolle N; Alfaro A; Tran DTN; Garberis IJ; Talbot H; Christodoulidis S; Vakalopoulou M; Droin N; Stourm A; Kobayashi M; Kakegawa T; Lacroix L; Saulnier P; Job B; Deloger M; Jimenez M; Mahier C; Baris V; Laplante P; Kannouche P; Marty V; Lacroix-Triki M; Diéras V; André F
Nat Med; 2023 Aug; 29(8):2110-2120. PubMed ID: 37488289
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
